Boston expands board, appoints tech specialist
This article was originally published in Clinica
Executive Summary
Boston Scientific has appointed technology investor David Roux to its board, increasing the number of directors from 10 to 11, effective 1 January 2014. Mr Roux is a co-founder and director of Silver Lake, a private equity firm focused on technology investing. Before this, he was chair and CEO of troubled software developer Liberate Technologies, executive vice-president of its parent company and IT specialist Oracle, and senior vice-president of Lotus Development, which was acquired by computing giant IBM in 1995. The appointment comes as Boston attempts to turn the corner on a difficult few years, and some have speculated that Mr Roux could aid the firm’s M&A strategy in areas outside its core medical device expertise. This could include healthcare IT, which rival Medtronic made a move into earlier this year, buying telehealth specialist Cardiocom in August.